iShares Biotechnology ETF
710 hedge funds and large institutions have $6.41B invested in iShares Biotechnology ETF in 2019 Q4 according to their latest regulatory filings, with 171 funds opening new positions, 153 increasing their positions, 231 reducing their positions, and 48 closing their positions.
256% more first-time investments, than exits
New positions opened: 171 | Existing positions closed: 48
22% more funds holding in top 10
Funds holding in top 10: 9 → 11 (+2)
22% more capital invested
Capital invested by funds: $5.25B → $6.41B (+$1.16B)
19% more funds holding
Funds holding: 597 → 710 (+113)
5.66% more ownership
Funds ownership: 78.5% → 84.16% (+5.7%)
34% less repeat investments, than reductions
Existing positions increased: 153 | Existing positions reduced: 231
43% less call options, than puts
Call options by funds: $692M | Put options by funds: $1.22B
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$192M |
| 2 |
Goldman Sachs
New York
|
+$192M |
| 3 |
Citigroup
New York
|
+$154M |
| 4 |
Public Sector Pension Investment Board (PSP Investments)
Montreal,
Quebec, Canada
|
+$32.1M |
| 5 |
SMM
Stadion Money Management
Watkinsville,
Georgia
|
+$25.1M |
Top Sellers
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$207M |
| 2 |
JP Morgan Chase
New York
|
-$180M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$157M |
| 4 |
N
Natixis
Paris,
France
|
-$125M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$63.8M |
IBB Hedge Fund Activity: Q4 2019 in Review
710 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q4 2019, worth a combined $6.41B — up 22% from $5.25B a quarter earlier.
Buyers outnumbered sellers: 171 funds opened new IBB positions and 48 closed out — a net gain of 123 holders — while 153 added to existing stakes and 231 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $192M. The largest seller was Bank of America, cutting an estimated $207M.
- 710 institutional investors held iShares Biotechnology ETF (IBB) as of Q4 2019, up from 597 in Q3 2019.
- Funds reported $6.41B of iShares Biotechnology ETF stock for Q4 2019, up 22% quarter-over-quarter.
- 171 funds opened new iShares Biotechnology ETF positions in Q4 2019 and 48 closed out, a net change of +123 holders.
- The largest iShares Biotechnology ETF buyer in Q4 2019 was Morgan Stanley, an estimated $192M added.
- The largest iShares Biotechnology ETF seller in Q4 2019 was Bank of America, an estimated $207M sold.
Based on aggregated 13F filings for Q4 2019.